Thomas Schall, ChemoCentryx CEO
After skepticism and tight vote at adcomm, FDA approves ChemoCentryx's rare disease drug
After a tight advisory committee vote back in May that tilted just slightly in favor of approving ChemoCentryx’s avacopan, the FDA has officially cleared …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
